-+ 0.00%
-+ 0.00%
-+ 0.00%

According to the Zhitong Finance App, Insi Intelligence (03696.HK) announced that ISM8969/HT-001, an innovative oral NLRP3 inhibitor jointly developed by the company and Shenzhen Hengtai Biotechnology Co., Ltd. (Hengtai Biology) has obtained clinical trial approval for a new drug from the China National Drug Administration (NMPA) to treat Parkinson's disease. Following the announcement of the first human administration in the Australian Phase I study in June 2026, this approval marks the official launch of parallel clinical evaluations in China and Australia.

Zhitongcaijing·08/03/2026 00:33:09
Listen to the news
According to the Zhitong Finance App, Insi Intelligence (03696.HK) announced that ISM8969/HT-001, an innovative oral NLRP3 inhibitor jointly developed by the company and Shenzhen Hengtai Biotechnology Co., Ltd. (Hengtai Biology) has obtained clinical trial approval for a new drug from the China National Drug Administration (NMPA) to treat Parkinson's disease. Following the announcement of the first human administration in the Australian Phase I study in June 2026, this approval marks the official launch of parallel clinical evaluations in China and Australia.